Plant Overview
Uni Medicolabs Limited has 2 state of the art manufacturing facilities.
The manufacturing facility I is built according to International regulatory guidelines and is approved by EU GMP, TGA Australia, SAUMP Ukraine, FDA Philippines, FMHACA Ethiopia & many others. The facility is spanned over a total area of 8,000 sq.mt.
This facility is capable of manufacturing tablets, hard gelatin capsules, oral liquids, dry powder syrups, stick packs and semi-solid external preparations in large capacities to meet ever increasing demand of the market.
The manufacturing facility II has been build to comply with regulated market standards with a total area of 3,300 sq.mt. and provided with latest state of art equipment. This facility is capable of manufacturing hard gelatin capsules and oral liquids.
POLAND – GENERAL INJECTABLES SITE
Located in Warsaw, Poland, this 14000 square meter facility comes with 2200 square meters of built-up production area and another 1000 square meters of warehouse capacity. Catering to key global markets with our portfolio, we are also a preferred CMO partner for supplying injectable medications locally in Europe. This EU GMP approved facility houses four production lines consisting of an ampoule line, a pre-filled syringe line, a high-speed liquid and a separate vial line with both liquid and lyophilization capabilities.
Facility Approvals – US FDA, EU GMP, Health Canada
INDIA – CARBAPENEMS SITE
Steriscience acquired a majority stake in Brooks in 2021 gaining access to a dedicated Carbapenems facility located in Gujarat, India. Set up in the year 2015, the facility today has a 150 strong workforce and is situated on an area covering 66000 square meters with 11000 square meters of built-up areas covering production, quality control laboratories, warehouse, and administration blocks. Already catering to patients in key emerging markets including India, we received our first ANDA approval from this facility August 2022, and will be launching first set of products in the US and Europe markets.
Our supply chain for anti-infectives is further strengthened with recent investments in a greenfield API manufacturing unit at this facility, making Steriscience one of the few fully integrated players for Carbapenems globally, while ensuring cost competitiveness.
Facility Approvals – US FDA, EU GMP, ANVISA, CDSCO
INDIA – GENERAL INJECTABLES
Located in Bengaluru, India, this state-of-the-art USFDA approved facility offers a wide range of parenteral drug products with over two decades of experience supplying to the US, Europe and Australia markets. Situated on an area covering 6500 square meters, the facility consists of a 300+ strong workforce with three production lines.
The site has industry-leading expertise in lyophilization techniques and tremendous experience in cycle-time optimization. The facility also hosts an autoinjector device line that allows us to offer patient-friendly drug delivery solutions with capacities to produce 16 million autoinjectors annually.
Facility Approvals – US FDA, TGA, Health Canada
54 Million
Ampoules
121 Million
Liquid Vials
40 Million
Dry powder Vials
20 Million
Lyophilized Vials
36 Million
Autoinjectors
28 Million
Pre-filled Syringes
Gallery
Plant Views
